CHMP Recommends Brodalumab (Kyntheum) for Plaque Psoriasis CHMP Recommends Brodalumab (Kyntheum) for Plaque Psoriasis

The EMA ' s CHMP has recommended granting marketing authorization for brodalumab (Kyntheum, LEO Pharma, A/S) for the treatment of adults with moderate to severe plaque psoriasis.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Alert Source Type: news